Luye Pharma
Luye Pharma Group is a leading specialty pharmaceutical company based on research and development.
Launch date
Employees
Market cap
€1.2b
Enterprise valuation
€1.5b (Public information from Sep 2024)
Share price
HKD2.98 2186.HK
Wauchula Florida (HQ)
Financials
Estimates*
CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 5.5b | 5.2b | 6.0b | 6.1b | 6.8b | 7.8b | 8.9b |
% growth | (13 %) | (6 %) | 15 % | 3 % | 11 % | 14 % | 14 % |
EBITDA | 1.9b | 969m | 1.9b | 1.9b | 1.8b | 2.1b | 2.4b |
% EBITDA margin | 35 % | 19 % | 32 % | 31 % | 27 % | 27 % | 27 % |
Profit | 707m | (134m) | 605m | 533m | 736m | 1.0b | 1.3b |
% profit margin | 13 % | (3 %) | 10 % | 9 % | 11 % | 13 % | 14 % |
EV / revenue | 2.9x | 3.3x | 2.6x | 2.6x | 1.9x | 1.6x | 1.4x |
EV / EBITDA | 8.2x | 17.5x | 8.3x | 8.3x | 7.1x | 6.2x | 5.2x |
R&D budget | 790m | 683m | 857m | 586m | - | - | - |
R&D % of revenue | 14 % | 13 % | 14 % | 10 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
* | CNY1.6b | Post IPO Equity | |
Total Funding | - |
Recent News about Luye Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Luye Pharma
EditACQUISITION by Luye Pharma Dec 2019